Fireside Chat – TargED
During these talks, we ask experienced and successful Life Science entrepreneurs to come and share their experiences with the up-and-coming entrepreneurs in the unlock_ community.
The Fireside Chats are a great way to ask questions and hear personal experiences from successful Life Science entrepreneurs.
This event is open to all life science and biotech startups in the Leiden Bio Science Park community.
Join us on September 15 with Kristof Vercruysse, CEO of TargED.
- Date: 15-09-2022
- Time: 15:00 – 17:00
- Location: Startup Zone, BioPartner 5 De Limes 7, 2342 DH Oegstgeest
About the speaker
Kristof Vercruysse has over 15 years of experience in bringing biopharmaceutical compounds from preclinical proof of concept towards market authorization. Kristof gained hands-on experience with the development of Caplacizumab for treatment of TTP at Ablynx between 2007 and 2013. Subsequently, he joined Sourcia, a full-service boutique CRO that delivers tailor-made clinical drug development for biotech companies. Kristof holds a Masters in Biomedical Science from Vrije Universiteit Brussel.
About TargED
TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.
TargED, a spin-off of the University Medical Center Utrecht, was founded in July 2020 by Associate Professor at the Department of Clinical Chemistry and Haematology, Coen Maas, PhD, an expert in thrombosis and hemostasis, Steven de Maat, PhD, an expert in recombinant protein development and optimization, Marc van Moorsel, researcher with focus on Acute Ischemic Stroke and Kristof Vercruysse, with more than 20 years of experience in bringing biopharmaceutical compounds from pre-clinical proof of concept to market, most notably, Caplacizumab for Thrombotic Thrombocytopenic Purpura at Ablynx between 2007 and 2013.
